FIG. 1


sFRα in log2 scale
Distribution of logsfr
logsfr
3.5
4.5
5.5
6.5
7.5
8.5
9.5
10.5
0
10
20
30
40
sFRα in original scale
Distribution of LBSTRESN
Numeric Result/Finding in Standard Units
Percent
0
200
400
600
800
1000
1200
1400
0
20
40
60
80

FIG. 2

Clinical Parameter	Statistics	<Q1 (N=42)	>=Q1 to <median (Q2) (N=43)	>=median (Q2) to <Q3 (N=42)	>=Q3 (N=43)
PFS BIRC	n	42	43	42	43
	Events, n(%)	33 (79)	34 (79)	30 (71)	25 (58)
	Median	2.9	4.0	4.1	5.5
	95% CI of Median	2.30, 4.40	2.76, 4.27	2.92, 6.77	4.17, 14.26
PFS INV	n	42	43	42	43
	Events, n(%)	38 (90)	34 (79)	34 (81)	31 (72)
	Median	3.0	4.2	4.9	6.9
	95% CI of Median	2.66, 4.96	3.02, 5.06	4.11, 5.88	4.17, 8.44
OS	n	42	43	42	43
	Events, n(%)	16 (38)	17 (40)	16 (38)	14 (33)
	Median	--	20.5	18.7	--
	95% CI of Median	10.32, --	9.10, 20.50	11.10, 18.69	11.07, --
ORR BIRC	n	42	43	42	43
	Responders, n(%)	5 (12)	8 (19)	9 (21)	14 (33)
	95% CI for ORR	4.0, 25.6	8.4, 33.4	10.3, 36.8	19.1, 48.5
ORR INV	n	42	43	42	43
	Responders, n(%)	6 (14)	12 (28)	14 (33)	18 (42)
	95% CI for ORR	5.4, 28.5	15.3, 43.7	19.6, 49.5	27.0, 57.9

FIG. 3



Note: p-value is from unstratified log-rank test


PS2 vs soluble FR alpha
PERCENT
40
30
20
10
0
Low
Medium
High
Fralpha expression level based on PS2
Soluble FR alpha quartiles:
1
2
3
4

FIG. 4

FIG. 5



FIG. 6A



Trial	Number of Patients	Median sFRα (ng/mL)
FORWARD I	259	2.2
MIRASOL	440	0.8
SORAYA	110	1.7
Combined Trials	809	1.2

FIG. 6B



* 2 samples were omitted from the FORWARD I analysis with sFRα levels 0 ng/mL

FIG. 7A



FIG. 7B



Dataset	Number of Patients	Median sFRα (ng/mL)
PS2 0-24	86	0.61
PS2 25-49	53	0.74
PS2 50-74	94	0.75
PS2 ≥ 75	171	1.1
Total Trial	440*	0.8

* There were 440 patients with sFRα. Only 404 of these also had IHC FRα PS2 score.

FIG. 8A


PS2 (% viable tumor cells with 2+ or 3+ FRα membrane staining)
150
100
50
0
Positive PS2
R^2 = 0.05773
2^{-3} 2^{-2} 2^{-1} 2^{0} 2^{1} 2^{2} 2^{3} 2^{4} 2^{5} 2^{6}
$\log_2$ sFRα (ng/mL)

FIG. 8B



n= 404 patients with matched IHC PS2 score and sFRα reads

FIG. 9A


PS2 High (≥ 75) Patients
n=50
36%
64%
sFRα Low
sFRα High
PS2 Med-Low (< 75) Patients
n=69
40.58%
59.42%
sFRα Low
sFRα High
Q1 and Q2 sFRα
n=59
30.51%
52.54%
16.95%
PS2 < 50
PS2 50-74
PS2 ≥ 75
Q3 sFRα
n=30
46.67%
26.67%
26.67%
PS2 < 50
PS2 50-74
PS2 ≥ 75
Q4 sFRα
n=30
10%
30%
60%
PS2 < 50
PS2 50-74
PS2 ≥ 75

FIG. 9B


Patients with PS2 0-24
n=86
29%
71%
Patients with PS2 25-49
n=53
36%
64%
Patients with PS2 50-74
n=94
48%
52%
Patients with PS2 (≥ 75)
n=171
63%
37%
sFRα Low < Median (0.8ng/mL, n =440)
sFRα High ≥ Median (0.8ng/mL, n =440)
Q1 and Q2 sFRα
n=202
31%
29%
24%
16%
Q3 sFRα
n=100
45%
18%
12%
25%
Q4 sFRα
n=102
63%
9%
9%
20%
PS2 0-24
PS2 25-49
PS2 50-74
PS2 ≥ 75

FIG. 10


sFRalpha (pg/mL) by ELISA
100
1000
10000
sFRalpha(pg/mL) by MassSpec
1000
10000
100000

FIG. 11



	Q1	Q2	Q3	Q4
PFSinv n # events (%) Median (95% CI) months	40 36 (90.0) 2.96 (2.66, 4.24)	42 35 (83.3) 4.11 (2.92, 4.50)	43 33 (76.7) 4.60 (4.04, 7.03)	42 31 (73.8) 6.90 (4.40, 7.36)
PFSbirc n # events (%) Median (95% CI) months	40 32 (80.0) 2.91 (2.23, 4.17)	42 29 (69.0) 4.11 (2.79, 5.59)	43 33 (76.7) 4.04 (2.76, 5.68)	42 24 (57.1) 5.75 (4.21, 14.26)
ORRinv n # responders (%) 95% CI for ORR	40 7 (17.5) 7.3, 32.8	42 11 (26.2) 13.9, 42.0	43 16 (37.2) 23.0, 53.3	42 17 (40.5) 25.6, 56.7
ORRbirc n # responders (%(95% CI for ORR	40 8 (20.0) 9.1, 35.6	42 9 (21.4) 10.3, 36.8	43 10 (23.3) 11.8, 38.6	42 16 (38.1) 23.6, 54.4